226700-79-4|福沙那韦|Fosamprenavir|MFCD09955118-范德生物科技公司

福沙那韦

NMR下载 COA and HPLC MSDS下载
names：
Fosamprenavir
CAS号：
226700-79-4
MDL Number： MFCD09955118
MF(分子式)： C25H36N3O9PS MW(分子量)： 585.61
EINECS:No data available Reaxys Number:No data available
Pubchem ID:131536 Brand:BIOFOUNT

福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)Fosamprenavir，也称为GW433908，Lexiva和Telzir，是蛋白酶抑制剂（PI）氨普那韦的口服前药。Fosamprenavir与其他抗逆转录病毒药物合用，可用于治疗HIV感染的患者，尤其是以前未接受过抗逆转录病毒治疗的患者。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000661-5mg	5mg	99.94%	¥ 2531.00	¥ 2531.00		2-3天	- +	¥ 0.00
YZM000661-1mg	1mg	99.94%	¥ 1218.75	¥ 1218.75		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	福沙那韦(226700-79-4),富山那韦,夫沙那韦;（3-（（（（4-氨基苯基）磺酰基）（2-甲基丙基）氨基）-1-（苯基甲基）-2-（膦酰氧基）丙基）氨基甲酸C-（四氢-3-呋喃基）;
英文别名	Fosamprenavir(226700-79-4);fos-amprenavir;fosamprenavir;fosamprenavir calcium;GW 433908;GW 433908G;GW 908;GW-433908;GW-433908G;GW-908;GW433908;GW433908G;GW908 cpd;Lexiva;VX 175;VX-175;VX175 cpd;(3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester fos-amprenavir;
CAS号	226700-79-4
SMILES	O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O)(O)=O)CN(S(=O)(C3=CC=C(N)C=C3)=O)CC(C)C
Inchi	InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
InchiKey	MLBVMOWEQCZNCC-OEMFJLHTSA-N
分子式 Formula	C25H36N3O9PS
分子量 Molecular Weight	585.61
闪点 FP	No data available
熔点 Melting point	No data available
沸点 Boiling point	No data available
Polarizability极化度	57.3±0.5 10-24cm3
密度 Density	1.4±0.1 g/cm3
蒸汽压 Vapor Pressure	6.1X10-11 mm Hg在25°C（est）
溶解度Solubility	生物体外In Vitro:DMSO溶解度≥ 100 mg/mL(170.76 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状	灰白色固体粉末,Power
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)毒理性质：

Some degree of serum aminotransferase elevations occur in a high proportion of patients taking amprenavir or fosamprenavir containing antiretroviral regimens. In large, multicenter trials of fosamprenavir based antiretroviral therapy, moderate-to-severe elevations in serum aminotransferase levels (>5 times the upper limit of normal) were found in 3% to 10% of patients. Rates of enzyme elevations are higher in patients with HIV-HCV coinfection then in those with monoinfection. These elevations are usually asymptomatic and self-limited and can resolve even with continuation of the medication. Furthermore, similar rates of enzyme elevations were found in comparator arms (using other HIV protease inhibitors). Clinically apparent acute liver injury due to amprenavir or fosamprenavir is rare and the specific clinical features have not been characterized in any detail. The few cases of symptomatic liver injury that have been reported have arisen after 1 to 8 weeks of starting the agent, and the pattern of serum enzyme elevations has not been well defined, but probably largely hepatocellular (Cases 1 and 2). Signs of hypersensitivity (fever, rash, eosinophilia) can occur, but autoantibody formation is rare. The acute liver injury due to HIV protease therapy is usually self-limited, but it can be severe, and isolated cases of acute liver failure have been reported with some agents. In HBV or HCV coinfected patients, acute liver injury may be caused by an exacerbation of the underlying chronic liver disease, perhaps as a result of sudden immune reconstitution. Neither amprenavir nor fosamprenavir have been clearly linked to lactic acidosis and acute fatty liver that is reported in association with several nucleoside analogue reverse transcriptase inhibitors. Likelihood score: D (possible rare cause of clinically apparent liver injury)

福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：福沙那韦试剂,福沙那韦杂质,福沙那韦中间体,福沙那韦密度,福沙那韦合成,福沙那韦溶解度,福沙那韦旋光度,福沙那韦结构式,福沙那韦闪点,福沙那韦MSDS,

产品说明	福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)是抗逆转录病毒蛋白酶的抑制剂Amprenavir的磷酸酯前药.
Introduction	福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. AntiIVinfection.
Application1	福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)是蛋白酶抑制剂安普那韦的前药，,具有改善的溶解性。
Application2
Application3

福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)药理学：

※福沙那韦具有基于磺酰氨基的结构的磺酰胺，其在磺酰胺氮上被（2R，3S）-4-苯基-2-（膦酰氧基）-3-（{[（（3S;）-四氢呋喃-3-基氧基]羰基}氨基）丁基基团。它是HIV蛋白酶抑制剂和抗逆转录病毒药物氨普那韦的前药。

※Fosamprenavir是氨普那韦的前药形式。fosamprenavir在体内被代谢为氨普那韦，后者是羟乙基胺磺酰胺的合成衍生物，能选择性结合并抑制人类免疫缺陷病毒（HIV）蛋白酶。

※Fosamprenavir，也称为fos-apv或VX175 CPD，属于称为氨基苯磺酰胺的有机化合物。这些是含有苯磺酰胺部分的有机化合物，该部分具有连接在苯环上的胺基。福沙那韦被认为是实际上不溶的（在水中）并且是相对中性的分子。已在多种生物流体（如尿液和血液）中检测到福沙那韦。在细胞内，fosamprenavir主要位于细胞质和膜中（由logP预测）。磷酰胺可以由磺酰胺生物合成。

※福沙那韦是基于该结构的磺酰胺磺胺对磺酰胺取代的氮通过（2R，3S）-4-苯基-2-（膦酰氧基）-3 - （{[（3S） -四氢呋喃-3-基氧基]羰基}氨基）丁基。它是HIV蛋白酶抑制剂和抗逆转录病毒药Amprenavir的前药。它具有前药作用。它衍生自磺胺。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)危害标识：

象形图


信号	Warning
GHS危险说明	Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
	H315 (33.33%): Causes skin irritation [Warning Skin corrosion/irritation]
	H351 (66.67%): Suspected of causing cancer [Warning Carcinogenicity]
	H361 (33.33%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
	H373 (33.33%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
	Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范说明代码	P201, P202, P260, P264, P280, P281, P302+P352, P308+P313, P314, P321, P332+P313, P362, P405, and P501
防范说明代码	(The corresponding statement to each P-code can be found at the GHS Classification page.)

Falcoz C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98.

Stereoselective Synthesis of the Key Intermediates of the HIV Protease Inhibitor Fosamprenavir and Its Diastereomer Synlett 2013 10.1055/s-0033-1338803

25811541 2015-05-18 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis Chemical research in toxicology

22821809 2012-12-01 Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors Proteins

23084317 2012-11-01 A case of adverse drug reaction induced by dispensing error Journal of forensic and legal medicine

福沙那韦(226700-79-4,Fosamprenavir,GW433908,Lexiva,Telzir)参考文献：

1、Case Study: Fosamprenavir: A Prodrug of Amprenavir Hui Ouyang

Abstract：Fosamprenavir (Lexiva®) is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir (Agenerase®). Amprenavir is a white-to-cream-colored solid with a solubility of approximately 0.04 mg/mL in water at 25°C. It was originally marketed as an oral solution at a concentration of 15 mg/mL that included a variety of excipients, such as acesulfame potassium, artificial grape bubblegum flavor, citric acid, TPGS, menthol, natural peppermint flavor, polyethylene glycol 400, propylene glycol, saccharin sodium, sodium chloride, and sodium citrate (GlaxoSmithKline, 2004). Because the recommended amprenavir regimen is 1200 mg twice daily (equal to 80 mL b.i.d.), the large amount of excipients (propylene glycol in particular) in the oral solution posed potential toxicity problems and prohibited its usage in infants and children under the age of 4 years and in certain other patient populations. Amprenavir is also formulated as capsules in strengths of 50 and 150 mg (GlaxoSmithKline, 2002). The content of vitamin E as TPGS in amprenavir capsules (daily dose of 1744 IU) far exceeds the Reference Daily Intake (adults 30 IU, pediatrics 10 IU). Patients are advised not to take additional vitamin E. To reduce the excipient intake and the burden of 8 capsules twice daily, fosamprenavir was designed as a more watersoluble prodrug (0.31 mg/mL in water at 25°C) of amprenavir (Gatell, 2001), which required only two tablets twice a day.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开